R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm
MyelomaXIV
Phase 3 small_molecule active
Quick answer
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm for Multiple Myeloma is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Multiple Myeloma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active